Literature DB >> 27486202

Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.

Yingqiang Zhang1, Guihua Huang2, Yu Wang1, Lijian Liang3, Baogang Peng3, Wenzhe Fan1, Jianyong Yang4, Yonghui Huang4, Wang Yao1, Jiaping Li5.   

Abstract

INTRODUCTION: This study evaluated long-term outcomes of salvage surgery as additional therapy following downstaging of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) in patients with initially unresectable HCC.
METHODS: A retrospective analysis was performed of 831 consecutive patients with unresectable HCC who underwent TACE as initial treatment between June 2004 and December 2014. Of these, 82 patients with downstaged resectable HCC were enrolled in this study: 43 received salvage surgery (S group) and the remaining 39, who refused salvage resection, were the control group (T group). The primary endpoint was overall survival (OS).
RESULTS: The median OS in the S and T groups was 49 and 31 months, respectively (p = .027). The 2-, 4-, and 5-year survival rates were 93%, 47%, and 26% in the S group and 74%, 18%, and 10% in the T group, respectively (p = .019). Treatment modality (hazard ratio [HR], 0.337; 95% confidential interval [CI], 0.184-0.616; p < .001) and response to TACE (complete vs. partial; HR, 3.154; 95% CI, 1.709-5.822; p < .001) were independent prognostic factors for survival. The median OS for patients in the complete response and partial response (PR) subgroups was 50 and 49 months, respectively, in the S group and 54 and 24 months, respectively, in the T group (p = .699 and p < .001, respectively). The median OS for HCC patients with macroscopic vascular invasion (MVI) was 58 and 30 months in the S and T groups, respectively (p = .024).
CONCLUSION: Salvage surgery after downstaging of unresectable HCC had a survival benefit only for patients with MVI or a PR to TACE. IMPLICATIONS FOR PRACTICE: The results of this study suggest that salvage liver resection after downstaging of unresectable hepatocellular carcinoma in patients with a complete response to transarterial chemoembolization (TACE) has a comparable long-term outcome in this good-prognosis group. Salvage liver resection may provide a better long-term outcome compared with TACE alone, but only in patients with macroscopic vascular invasion or those with a partial response to TACE. ©AlphaMed Press.

Entities:  

Keywords:  Downstaging; Hepatocellular carcinoma; Overall survival; Salvage surgery; Transarterial chemoembolization

Mesh:

Year:  2016        PMID: 27486202      PMCID: PMC5153353          DOI: 10.1634/theoncologist.2016-0094

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  21 in total

Review 1.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

2.  Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Baogang Peng; Lijian Liang; Qiang He; Fan Zhou; Shimin Luo
Journal:  Hepatogastroenterology       Date:  2006 May-Jun

Review 3.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

4.  A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.

Authors:  Francis Y Yao; Ryutaro Hirose; Jeanne M LaBerge; Timothy J Davern; Nathan M Bass; Robert K Kerlan; Raphael Merriman; Sandy Feng; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Liver Transpl       Date:  2005-12       Impact factor: 5.799

5.  Salvage surgery following downstaging of unresectable hepatocellular carcinoma.

Authors:  Wan-yee Lau; Stephen K W Ho; Simon C H Yu; Eric C H Lai; Choong-tsek Liew; Thomas W T Leung
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

Review 6.  Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability.

Authors:  Wan Yee Lau; Eric C H Lai
Journal:  Ann Surg Oncol       Date:  2007-09-22       Impact factor: 5.344

7.  Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.

Authors:  Francis Y Yao; Robert K Kerlan; Ryutaro Hirose; Timothy J Davern; Nathan M Bass; Sandy Feng; Marion Peters; Norah Terrault; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

8.  Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.

Authors:  William C Chapman; M B Majella Doyle; Jourdan E Stuart; Neeta Vachharajani; Jeffrey S Crippin; Christopher D Anderson; Jeffrey A Lowell; Surendra Shenoy; Michael D Darcy; Daniel B Brown
Journal:  Ann Surg       Date:  2008-10       Impact factor: 12.969

Review 9.  Improved outcome for children with hepatoblastoma.

Authors:  M D Stringer; S Hennayake; E R Howard; L Spitz; E A Shafford; G Mieli-Vergani; R Saxena; M Malone; C Dicks-Mireaux; J Karani
Journal:  Br J Surg       Date:  1995-03       Impact factor: 6.939

10.  Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.

Authors:  Yingqiang Zhang; Wenzhe Fan; Yu Wang; Ligong Lu; Sirui Fu; Jianyong Yang; Yonghui Huang; Wang Yao; Jiaping Li
Journal:  Oncologist       Date:  2015-10-07
View more
  13 in total

1.  25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.

Authors:  Y-Q Wu; W-Z Fan; M Xue; J Guo; J-L Wei; Y Wang; W Yao; Y Zhao; J-P Li
Journal:  Clin Transl Oncol       Date:  2019-06-10       Impact factor: 3.405

2.  Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.

Authors:  Yanqin Wu; Wenzhe Fan; Miao Xue; Bihui Zhong; Shenghong Zhang; Yu Wang; Wang Yao; Yue Zhao; Jiaping Li
Journal:  Oncologist       Date:  2019-06-27

Review 3.  Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).

Authors:  Hui-Chuan Sun; Jian Zhou; Zheng Wang; Xiufeng Liu; Qing Xie; Weidong Jia; Ming Zhao; Xinyu Bi; Gong Li; Xueli Bai; Yuan Ji; Li Xu; Xiao-Dong Zhu; Dousheng Bai; Yajin Chen; Yongjun Chen; Chaoliu Dai; Rongping Guo; Wenzhi Guo; Chunyi Hao; Tao Huang; Zhiyong Huang; Deyu Li; Gang Li; Tao Li; Xiangcheng Li; Guangming Li; Xiao Liang; Jingfeng Liu; Fubao Liu; Shichun Lu; Zheng Lu; Weifu Lv; Yilei Mao; Guoliang Shao; Yinghong Shi; Tianqiang Song; Guang Tan; Yunqiang Tang; Kaishan Tao; Chidan Wan; Guangyi Wang; Lu Wang; Shunxiang Wang; Tianfu Wen; Baocai Xing; Bangde Xiang; Sheng Yan; Dinghua Yang; Guowen Yin; Tao Yin; Zhenyu Yin; Zhengping Yu; Bixiang Zhang; Jialin Zhang; Shuijun Zhang; Ti Zhang; Yamin Zhang; Yubao Zhang; Aibin Zhang; Haitao Zhao; Ledu Zhou; Wu Zhang; Zhenyu Zhu; Shukui Qin; Feng Shen; Xiujun Cai; Gaojun Teng; Jianqiang Cai; Minshan Chen; Qiang Li; Lianxin Liu; Weilin Wang; Tingbo Liang; Jiahong Dong; Xiaoping Chen; Xuehao Wang; Shusen Zheng; Jia Fan
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

4.  Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses.

Authors:  Crisanta H Ilagan; Debra A Goldman; Mithat Gönen; Victoria G Aveson; Michelle Babicky; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; Alice C Wei; T Peter Kingham; Ghassan K Abou-Alfa; Karen T Brown; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2022-07-15       Impact factor: 4.339

5.  Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma.

Authors:  Yingqiang Zhang; Guihua Huang; Hongfei Miao; Ze Song; Xiaoying Zhang; Wenzhe Fan; Yu Wang; Jiaping Li; Yong Chen
Journal:  Ther Adv Med Oncol       Date:  2020-07-23       Impact factor: 8.168

6.  Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?

Authors:  Ze-Feng Zhang; Yu-Jun Luo; Quan Lu; Shi-Xue Dai; Wei-Hong Sha
Journal:  World J Clin Cases       Date:  2018-09-06       Impact factor: 1.337

Review 7.  Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.

Authors:  Clifford Akateh; Sylvester M Black; Lanla Conteh; Eric D Miller; Anne Noonan; Eric Elliott; Timothy M Pawlik; Allan Tsung; Jordan M Cloyd
Journal:  World J Gastroenterol       Date:  2019-07-28       Impact factor: 5.742

8.  Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection.

Authors:  Jiashuo Chao; Qi Zhu; Desheng Chen; Xiao An; Aiqun Liu; Fei Zhou; Lin Yuan; Zhaowen Wang; Hongcheng Sun
Journal:  Front Oncol       Date:  2021-03-29       Impact factor: 6.244

9.  Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis.

Authors:  Xinyu Chen; Lin Lai; Jiazhou Ye; Lequn Li
Journal:  Front Oncol       Date:  2021-11-19       Impact factor: 6.244

10.  Salvage surgery following downstaging of advanced non-small cell lung cancer by targeted therapy.

Authors:  Kuo Li; Xiaonian Cao; Bo Ai; Han Xiao; Quanfu Huang; Zheng Zhang; Qian Chu; Li Zhang; Xiaofang Dai; Yongde Liao
Journal:  Thorac Cancer       Date:  2021-06-15       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.